A5036926167- Lymphoma Diagnosis and Treatment
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- T-cell and Retrovirus Studies
- Cutaneous lymphoproliferative disorders research
- CAR-T cell therapy research
- Trauma and Emergency Care Studies
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Blood donation and transfusion practices
- Lung Cancer Treatments and Mutations
- Viral-associated cancers and disorders
- Peptidase Inhibition and Analysis
- Blood transfusion and management
- Medical Imaging Techniques and Applications
- Cancer Treatment and Pharmacology
- Medical Imaging and Pathology Studies
- Abdominal Trauma and Injuries
- Brain Metastases and Treatment
- Genetic factors in colorectal cancer
- Multiple Myeloma Research and Treatments
- Advanced Radiotherapy Techniques
Princess Margaret Cancer Centre
2024-2025
University Health Network
2024-2025
Monash University
2024
Monash Health
2021-2024
University of Toronto
2024
Moorabbin Hospital
2023
Geelong Hospital
2021-2023
Epworth Hospital
2020-2021
Central nervous system (CNS) relapse of lymphoma, also known as with secondary CNS lymphoma (SCNSL), is a rare but devastating complication that confers poor survival outcomes and treatment decision challenges. Diffuse large B-cell (DLBCL) accounts for most cases an incidence 4-6% commonly occurs within 1 year diagnosis (median 5 months). However, seen in the context other aggressive histological subtypes, such Burkitt mantle cell 20% 4%, respectively. Identifying patients at risk has been...
Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on histological continuum between 'lowgrade' (Grade 1, 2 and 3A FL) diffuse large B-cell (DLBCL) appearing to share features with each. Clinical characteristics outcomes are poorly understood due lack of adequate representation in prospective trials large-scale analyses. We analyzed 157 G3BFL cases from 18 international centers, two comparator groups; G3AFL (n=302) DLBCL (n=548). Composite histology or low-grade occurred...
Treatment of newly diagnosed diffuse large B‐cell lymphoma with rituximab and CHOP (R‐CHOP) has been largely unchanged for the last two decades. The Guideline by Fox et al. provides new evidence‐based therapeutic strategies informed positive results randomised clinical trials. Commentary on: management lymphoma: A British Society Haematology Guideline. Br J Haematol 2024; 204:1178‐1192.